Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
P53985
UPID:
MOT1_HUMAN
Alternative names:
Solute carrier family 16 member 1
Alternative UPACC:
P53985; Q49A45; Q5T8R6; Q9NSJ9
Background:
Monocarboxylate transporter 1 (MCT1), also known as Solute carrier family 16 member 1, plays a crucial role in cellular energy metabolism. It facilitates the bidirectional transport of monocarboxylates such as lactate, pyruvate, and ketone bodies across the plasma membrane, contributing to pH regulation and energy homeostasis.
Therapeutic significance:
MCT1's involvement in diseases like symptomatic deficiency in lactate transport, hyperinsulinemic hypoglycemia, and monocarboxylate transporter 1 deficiency highlights its potential as a therapeutic target. Understanding MCT1's role could open doors to novel treatments for these metabolic disorders.